PR Newswire·Nov 11, 2026, 7:00 AM ET

DecisionDx®-Melanoma Data at SDPA and Dermato-Onco2026 Support the Test's Ability to Refine Risk Assessment Beyond AJCC Staging

Castle Biosciences announced new DecisionDx-Melanoma data at the SDPA 24th Annual Fall Dermatology Conference (Nov 11-15, 2026) & the 3rd European Congress on Dermato-Oncology (Nov 12-13, 2026).
SDPA analysis of 750 patients with thin T1a melanomas found that 12% (1 in 8) had elevated melanoma-specific mortality risk despite traditional low-risk staging.
Five-year survival rates for T1a patients were 97.1% for Class 1A (lowest risk), 88.1% for Class 1B/2A (increased risk), & 86.2% for Class 2B (highest risk).
Dermato-Onco2026 oral presentation & poster evaluated 1,726 stage I–III melanoma patients to validate the i31-ROR algorithm for individualized five-year recurrence-risk estimates.
The i31-ROR algorithm predicted five-year recurrence more accurately than AJCC staging, distinguishing low-risk patients (92.5% recurrence-free survival) from high-risk patients (54.2% recurrence-free survival).
High-risk i31-ROR results correlated with significantly lower five-year distant metastasis-free survival (68.3%) & melanoma-specific survival (81.6%) compared to low-risk results (94.7% & 98.4% respectively).
Castle also presented an ePoster on AdvanceAD-Tx™, a 487-gene expression profile test for atopic dermatitis, showing improved outcomes for JAK inhibitor responders.
DecisionDx-Melanoma combines a 31-gene expression profile with clinicopathologic factors to provide personalized risk assessments for sentinel lymph node positivity & recurrence beyond standard staging.